Showing 4631-4640 of 5659 results for "".
- Meet Zerigo 2.0: Upgraded System Allows Patients to Better Manage Psoriasis and Eczema at Homehttps://practicaldermatology.com/news/meet-zerigo-20-upgraded-system-allows-patients-to-better-manage-psoriasis-and-eczema-at-home-2/2461681/Zerigo Health is rolling out the Zerigo 2.0 ecosystem, the newest iteration of its digital health platform for the treatment and management of chronic skin conditions like eczema and psoriasis to employers, health plans, and their provide
- 2023 Medscape Report: Physician Salaries Rise as Gender Gap Narrowshttps://practicaldermatology.com/news/2023-medscape-report-physician-salaries-rise-as-gender-gap-narrows/2461663/Doctor salaries continue to rise as the gender gap narrows, according to the 2023 Medscape Physician Compensation Report. The largest difference for women was seen in primary care, but the disparity also narrowed within specialties, from a 36% difference i
- Adding New Personalized Vaccine to Immunotherapy Slashes Risk for Melanoma Recurrencehttps://practicaldermatology.com/news/adding-new-personalized-vaccine-to-immunotherapy-slashes-risk-for-melanoma-recurrence/2461662/Adding an experimental mRNA vaccine to immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared with immunotherapy alone, a new clinical trial shows. The phase 2b trial results were presented at the annual meeting of the American A
- Lupus Research Alliance Collaborates with the FDA to Launch Public-Private Partnershiphttps://practicaldermatology.com/news/lupus-research-alliance-collaborates-with-the-fda-to-launch-public-private-partnership/2461641/The Lupus Research Alliance (LRA) announced the launched of Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a public-private partnership. The goal of the partnership is to bring people with lupus together in collaboration with the F
- Phase 3 Data Evaluating Almirall’s Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Publishedhttps://practicaldermatology.com/news/phase-3-data-evaluating-almiralls-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-published/2461640/Almirall announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, plac
- EON Robotic Body Contouring Device Receives Additional FDA Clearance for Back and Thighshttps://practicaldermatology.com/news/eon-robotic-body-contouring-device-receives-additional-fda-clearance-for-back-and-thighs/2461629/EON Smarter Body Contouring has received FDA clearance for the back and thighs—the third FDA clearance for EON. The device was previously FDA-cleared for clinical providers to treat patients' full abdomen and flanks. Parent company Dominion Aesthetic Technologies describe
- New Way to Measure Skin Barrier Function Identifiedhttps://practicaldermatology.com/news/new-way-to-measure-skin-barrier-function-identified/2461628/Scientists in Japan have devised a new way to measure skin barrier function. Most methods indirectly calculate skin barrier function using a proxy measure called transepidermal water loss (TEWL), but the dependance on a heavily controlled environment is one of the primary limitations of this
- HS Update: Studies Suggest TNF, IL-17, and JAK inhibitors May Play a Role in Treating HShttps://practicaldermatology.com/news/hs-update-studies-suggest-tnf-il-17-and-jak-inhibitors-may-play-a-role-in-treating-hs/2461627/Several new potential therapies for hidradenitis suppurativa (HS) are coming down the pike, according to research presented at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans. Acelyrin, Inc.'s Izokibep led to HiSCR response at 12 weeks, including H
- OliX Pharmaceuticals to Start Phase 1 Trial of Androgenic Alopecia Treatmenthttps://practicaldermatology.com/news/olix-pharmaceuticals-to-start-phase-1-trial-of-androgenic-alopecia-treatment/2461626/OliX Pharmaceuticals received regulatory approval to start Phase 1 trial of androgenic alopecia treatment in Australia. The trial is a multi-center, randomized, double-blind, placebo-controlled, and single ascending dose Phase 1 study. The primary objective of the study is to evalu
- Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL Studyhttps://practicaldermatology.com/news/timber-pharmaceuticals-announces-publication-of-sub-analysis-of-phase-2b-control-study/2461620/Timber Pharmaceuticals announced the online publication of a sub-analysis of the Phase 2b CONTROL study, which is evaluating TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, in subjects 9 years of age and older with moderate t